



The CCS is committed to preserving the scientific integrity of its Guidelines and Position Statements through transparency and management of potential conflicts of interest. All panel members must disclose all relationships with industry whether relevant to the guideline topic or not and potential conflicts are reviewed and assessed by the co-chairs and the CCS Guideline Committee. While the goal is to have the majority of a writing panel have no potential conflicts, this is not always feasible in today's medical landscape. When a potential conflict exists, the affected member must recuse during the formal consensus voting process. Below is a list of all disclosures for the AF panel, regardless of relevance to the 2018 AF Guideline Update. For more information on the CCS Guideline Development process, please visit www.ccs.ca.

| Member | Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline | | |
|----------------------|---|---|-------------------------|
| | Consulting Fees/ Honoraria | Clinical Trials | Other Financial Benefit |
| Primary Panel | | | |
| Laurent Macle | Abbott Canada, Bayer, BMS Pfizer, Boehringer Ingelheim, Johnson & Johnson, Servier | Johnson & Johnson, Servier | |
| Atul Verma | Bayer, Johnson & Johnson, Medtronic | Johnson & Johnson | |
| Jason Andrade | Bayer, BMS Pfizer, Medtronic, Servier | Medtronic, BMS-Pfizer, Bayer, Servier | |
| Clare Atzema | | | |
| Alan Bell | Amgen, AstraZeneca, Bayer, BMS Pfizer, Boehringer Ingelheim, Daiichi-Sankyo, Janssen, NovoNordisk, Servier | AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Janssen, Pfizer | |
| John Cairns | AstraZeneca, Bayer, BMS Pfizer, Servier | AstraZeneca, Boston Scientific | |
| Stuart Connolly | Bayer, BMS Pfizer, Servier | Abbott Canada, Bayer, BMS Pfizer, Boehringer Ingelheim, Medtronic | |
| Jafna Cox | Bayer, BMS Pfizer, Sanofi | | |
| Paul Dorian | Bayer, BMS Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, Servier | Bayer, BMS Pfizer, Boehringer Ingelheim, Servier | |
| David Gladstone | Bayer, BMS Pfizer, Boehringer Ingelheim | Bayer | |
| Jeff Healey | Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb | Abbott Canada, BMS Pfizer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Medtronic, Pfizer | |
| Kori Leblanc | Amgen, Bayer, BMS Pfizer, Boehringer Ingelheim, Servier | Boehringer Ingelheim | |
| M Sean McMurtry | | | |
| L Brent Mitchell | Bayer, BMS Pfizer, Boehringer Ingelheim, Medtronic, Servier | BMS Pfizer | |
| Girish M. Nair | Abbott | | |
| Stanley Nattel | Amgen | | |
| Ratika Parkash | Abbott Canada, Bayer, BMS Pfizer, Bristol-Myers Squibb, Medtronic, Pfizer, Servier, St. Jude Medical | Abbott Canada, Bayer | |



| Member | Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline | | |
|------------------------|--|--|-------------------------|
| | Consulting Fees/ Honoraria | Clinical Trials | Other Financial Benefit |
| Louise Pilote | | | |
| Jean-Francois Sarrazin | Abbott Canada, Johnson & Johnson | Boston Scientific | |
| Mike Sharma | Bayer, BMS Pfizer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Bristol-Myers Squibb, Daiichi-Sankyo | Bayer | |
| Allan Skanes | Bayer, BMS Pfizer, Boehringer Ingelheim, Johnson & Johnson | Johnson & Johnson, Medtronic | |
| Mario Talajic | Bayer, Bristol-Myers Squibb, Pfizer | Bristol-Myers Squibb, Pfizer | |
| Teresa Tsang | Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Pfizer | | |
| Subodh Verma | Amgen, AstraZeneca, Bayer, BMS Pfizer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Bristol-Myers Squibb, Eli Lilly, Janssen, Merck, Novartis, NovoNordisk, Pfizer, Sanofi, Servier, Mylan | Amgen, AstraZeneca, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Bristol-Myers Squibb, Eli Lilly | |
| D. George Wyse | | Portola | |
| Secondary Panel | | | |
| David Bewick | Amgen | | |
| Vidal Essebag | Abbott Canada, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Johnson & Johnson, Medtronic, Novartis, Pfizer, Servier | Abbott Canada, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Johnson & Johnson, Medtronic | |
| Peter Guerra | | | |
| Milan Gupta | | | |
| Brett Heilbron | Amgen, AstraZeneca, Bayer, BMS Pfizer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Pfizer, Sanofi, Servier | | |
| Paul Khairy | | Bayer | |
| Bob Kiaii | | | |
| George Klein | Boston Scientific, Medtronic | | |
| Simon Kouz | Bayer, BMS Pfizer, Boehringer Ingelheim, Servier | | |



| Member | Affiliations with commercial organizations within the previous two years that may have a direct or indirect connection to the content of this guideline | | |
|------------------|---|-----------------|-------------------------|
| | Consulting Fees/ Honoraria | Clinical Trials | Other Financial Benefit |
| Daniel Ngui | Amgen, AstraZeneca, BMS Pfizer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Merck, NovoNordisk, Pfizer, Sanofi, Servier | | Health Choices First |
| Pierre Pagé | | Abbott Canada | |
| Calum Redpath | | | |
| Jan Surkes | AstraZeneca, Bayer, BMS Pfizer, Boehringer Ingelheim, Boehringer Ingelheim / Eli Lilly Alliance, Bristol-Myers Squibb | Bayer | |
| Richard Whitlock | AstraZeneca, Amatheon, Atricure | Amatheon | |